CANY
CSTL icon

Caxton Associates (New York)’s Castle Biosciences CSTL Stock Holding History

Caxton Associates (New York)’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,876
Closed -$282K – 528
2024
Q3 		$282K Buy
+9,876
New +$251K 0.01% 449

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Caxton Associates (New York)'s CSTL Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Castle Biosciences (CSTL) in Q4 2024, closing a stake of 9,876 shares — an estimated $282K sold.

Caxton Associates (New York) first reported a position in CSTL in Q3 2024 and held it in 1 quarter. The position peaked at $282K in Q3 2024. 197 funds tracked by Wall St. Rank hold CSTL as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Castle Biosciences position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 9,876 Castle Biosciences shares in Q4 2024, an estimated $282K.
  • Caxton Associates (New York) first reported a position in Castle Biosciences in Q3 2024 and held it in 1 quarter.
  • Caxton Associates (New York)'s Castle Biosciences position peaked at $282K in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.